Takeda Pharmaceutical Company Limited (TYO:4502)
4,234.00
-46.00 (-1.07%)
May 9, 2025, 3:30 PM JST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Gastroenterology Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In |
Gastroenterology Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In |
PDT Immunology Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In |
PDT Immunology Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In |
Oncology Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In |
Oncology Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In |
Neuroscience Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In |
Neuroscience Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In |
Other Product Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In |
Other Product Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In |
Rare Metabolic |
Log In |
Log In |
Log In |
Log In |
Rare Metabolic Growth |
Log In |
Log In |
Log In |
Log In |
Rare Hematology |
Log In |
Log In |
Log In |
Log In |
Rare Hematology Growth |
Log In |
Log In |
Log In |
Log In |
Hereditary Angioedema |
Log In |
Log In |
Log In |
Log In |
Hereditary Angioedema Growth |
Log In |
Log In |
Log In |
Log In |
Rare Genetics and Other |
Log In |
Log In |
Log In |
Log In |
Rare Genetics and Other Growth |
Log In |
Log In |
Log In |
Log In |
Total Rare Diseases Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In |
Total Rare Diseases Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In |
Other Rare Disease |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Japan | 433.44B |
Log In |
Log In |
Log In |
Log In |
Japan Growth | -6.76% |
Log In |
Log In |
Log In |
Log In |
United States | 2,351.71B |
Log In |
Log In |
Log In |
Log In |
United States Growth | 8.50% |
Log In |
Log In |
Log In |
Log In |
Europe and Canada | 1,040.90B |
Log In |
Log In |
Log In |
Log In |
Europe and Canada Growth | 11.71% |
Log In |
Log In |
Log In |
Log In |
Asia (ex-Japan) | 281.64B |
Log In |
Log In |
Log In |
Log In |
Asia (ex-Japan) Growth | 15.07% |
Log In |
Log In |
Log In |
Log In |
Latin America | 250.93B |
Log In |
Log In |
Log In |
Log In |
Latin America Growth | 41.51% |
Log In |
Log In |
Log In |
Log In |
Russia / CIS | 89.13B |
Log In |
Log In |
Log In |
Log In |
Russia / CIS Growth | 32.85% |
Log In |
Log In |
Log In |
Log In |
Other Geographic | 131.32B |
Log In |
Log In |
Log In |
Log In |
Other Geographic Growth | 13.47% |
Log In |
Log In |
Log In |
Log In |